Skip to content

Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals

Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03959462
Enrollment
254
Registered
2019-05-22
Start date
2018-03-06
Completion date
2022-12-30
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Real tDCS, Sham tDCS

Keywords

tDCS

Brief summary

Decisions are part of the daily life. On the neuronal level, activity in the dorsolateral prefrontal cortex (dlPFC) is important during complex decisions (e.g., whether something is emotional for a person or not). We apply transcranial direct current stimulation (tDCS) with the aim to increase dlPFC activity and thereby modulate decisions towards emotional content.

Interventions

A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.

DEVICEsham transcranial direct current stimulation

A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.

Sponsors

Novartis
CollaboratorINDUSTRY
University of Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

Double blind design

Intervention model description

Participants are allocated to one of 2 groups: real tDCS or sham.

Eligibility

Sex/Gender
ALL
Age
20 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * Non-smokers * Right-handedness * Native German speakers or comparable level of fluency * Normal or corrected-to-normal vision

Exclusion criteria

* Neurological or psychiatric condition (other than diagnosed cognitive impairment) * Past head injuries * Magnetizable implants * History of seizures * Current or life-time alcohol or drug abuse * Skin diseases * tES in the 3 months preceding or during the present study * Caffeine 3 hours prior to training

Design outcomes

Primary

MeasureTime frameDescription
Influence of Stimulation on the Decisions10 minutesNumber of words which were rated as positive or negative.

Secondary

MeasureTime frameDescription
Profile of Mood States (POMS; before stimulation)3 minutesChanges in the subjective measure mood, assessed with questionnaire Scores for each item is recorded as 0 for not at all up to 6 for very strong. A Total Mood Disturbance (TMD) score is calculated by summing the totals for the negative subscales dejection (14 items), fatigue (7 items) and discontent (7 items) and then subtracting the total for the positive subscale zest (7 items).
Profile of Mood States (POMS; after stimulation)3 minutesChanges in the subjective measure mood, assessed with questionnaire Scores for each item is recorded as 0 for not at all up to 6 for very strong. A Total Mood Disturbance (TMD) score is calculated by summing the totals for the negative subscales dejection (14 items), fatigue (7 items) and discontent (7 items) and then subtracting the total for the positive subscale zest (7 items).
Positive and Negative Affect Schedule (PANAS; before stimulation)2 minutesChanges in the subjective measure mood, assessed with self-report questionnaire divided into two mood scales. One scale measures a person's positive emotion and the other scale measures the negative. Each segment has ten terms, which can be rated on a scale of 1 to 5 to indicate the extent to which the respondent agrees that this applies to him (higher values means higher agreement).
Positive and Negative Affect Schedule (PANAS; after stimulation)2 minutesChanges in the subjective measure mood, assessed with self-report questionnaire divided into two mood scales. One scale measures a person's positive emotion and the other scale measures the negative. Each segment has ten terms, which can be rated on a scale of 1 to 5 to indicate the extent to which the respondent agrees that this applies to him (higher values means higher agreement).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026